Pembrolizumab with standard chemo for ovarian small cell cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether adding pembrolizumab (an immune medicine) to standard chemotherapy can improve outcomes for people with small cell cancer of the ovary that has not been treated before. It may help your immune system recognize and attack the cancer while you receive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 12 or older, and your small cell ovarian cancer was confirmed by pathology (biopsy/surgery tissue).
- Your cancer stage is FIGO I to IV, and treatment starts either before or after the first chemo cycle (but you must begin study treatment within 4 weeks).
- Your health and strength are good enough for study treatment (ECOG performance status 0 or 1).
- Your blood counts and organs work well enough for chemotherapy (specific limits for white cells, neutrophils, platelets, hemoglobin, liver, kidneys, and heart function).
- You have not had prior chemotherapy beyond one cycle of platinum, and you have not had prior immune therapy like pembrolizumab or other PD-1/PD-L1/PD-L2 drugs.
- You cannot have certain infections or immune conditions (like active autoimmune disease needing immune medicines, significant lung inflammation needing steroids, active infection, HIV, hepatitis B/C, or TB).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
Hear when a new Small Cell Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.